Company profile
UK company 12420619, incorporated on 23 January 2020.
Genomic Technology for Cell & Gene Therapies
Our platform accelerates the characterisation of novel gene editing technologies to unlock the next wave of cell & gene therapies.
Company number 12420619
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
TM01 | Transaction MzU0NjUzNzY1MmFkaXF6a2N4
Published 23 Sep 2026 15:05
AA | Transaction MzUzOTA5NDY4NmFkaXF6a2N4
Published 17 Aug 2026 11:20
AD01 | Transaction MzUzODAwOTE2MGFkaXF6a2N4
Published 11 Aug 2026 12:06
Company registered at Companies House
Broken String Biosciences develops genome analysis technology.
Broken String Biosciences was formed to take advantage of the novel method INDUCE-seq that was developed during this award. The company aims to provide quantitative and accurate genome-wide DSB measurement to both industry and academic customers for a range of of biomedical applications.
VC seed funding secured in October 2021
No notable impacts at this time.
1 Jul 2025 to 30 Jun 2027
no public description
